Cargando…

Artificial intelligence-enabled screening for diabetic retinopathy: a real-world, multicenter and prospective study

INTRODUCTION: Early screening for diabetic retinopathy (DR) with an efficient and scalable method is highly needed to reduce blindness, due to the growing epidemic of diabetes. The aim of the study was to validate an artificial intelligence-enabled DR screening and to investigate the prevalence of D...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yifei, Shi, Juan, Peng, Ying, Zhao, Zhiyun, Zheng, Qidong, Wang, Zilong, Liu, Kun, Jiao, Shengyin, Qiu, Kexin, Zhou, Ziheng, Yan, Li, Zhao, Dong, Jiang, Hongwei, Dai, Yuancheng, Su, Benli, Gu, Pei, Su, Heng, Wan, Qin, Peng, Yongde, Liu, Jianjun, Hu, Ling, Ke, Tingyu, Chen, Lei, Xu, Fengmei, Dong, Qijuan, Terzopoulos, Demetri, Ning, Guang, Xu, Xun, Ding, Xiaowei, Wang, Weiqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7580048/
https://www.ncbi.nlm.nih.gov/pubmed/33087340
http://dx.doi.org/10.1136/bmjdrc-2020-001596
_version_ 1783598715443871744
author Zhang, Yifei
Shi, Juan
Peng, Ying
Zhao, Zhiyun
Zheng, Qidong
Wang, Zilong
Liu, Kun
Jiao, Shengyin
Qiu, Kexin
Zhou, Ziheng
Yan, Li
Zhao, Dong
Jiang, Hongwei
Dai, Yuancheng
Su, Benli
Gu, Pei
Su, Heng
Wan, Qin
Peng, Yongde
Liu, Jianjun
Hu, Ling
Ke, Tingyu
Chen, Lei
Xu, Fengmei
Dong, Qijuan
Terzopoulos, Demetri
Ning, Guang
Xu, Xun
Ding, Xiaowei
Wang, Weiqing
author_facet Zhang, Yifei
Shi, Juan
Peng, Ying
Zhao, Zhiyun
Zheng, Qidong
Wang, Zilong
Liu, Kun
Jiao, Shengyin
Qiu, Kexin
Zhou, Ziheng
Yan, Li
Zhao, Dong
Jiang, Hongwei
Dai, Yuancheng
Su, Benli
Gu, Pei
Su, Heng
Wan, Qin
Peng, Yongde
Liu, Jianjun
Hu, Ling
Ke, Tingyu
Chen, Lei
Xu, Fengmei
Dong, Qijuan
Terzopoulos, Demetri
Ning, Guang
Xu, Xun
Ding, Xiaowei
Wang, Weiqing
author_sort Zhang, Yifei
collection PubMed
description INTRODUCTION: Early screening for diabetic retinopathy (DR) with an efficient and scalable method is highly needed to reduce blindness, due to the growing epidemic of diabetes. The aim of the study was to validate an artificial intelligence-enabled DR screening and to investigate the prevalence of DR in adult patients with diabetes in China. RESEARCH DESIGN AND METHODS: The study was prospectively conducted at 155 diabetes centers in China. A non-mydriatic, macula-centered fundus photograph per eye was collected and graded through a deep learning (DL)-based, five-stage DR classification. Images from a randomly selected one-third of participants were used for the DL algorithm validation. RESULTS: In total, 47 269 patients (mean (SD) age, 54.29 (11.60) years) were enrolled. 15 805 randomly selected participants were reviewed by a panel of specialists for DL algorithm validation. The DR grading algorithms had a 83.3% (95% CI: 81.9% to 84.6%) sensitivity and a 92.5% (95% CI: 92.1% to 92.9%) specificity to detect referable DR. The five-stage DR classification performance (concordance: 83.0%) is comparable to the interobserver variability of specialists (concordance: 84.3%). The estimated prevalence in patients with diabetes detected by DL algorithm for any DR, referable DR and vision-threatening DR were 28.8% (95% CI: 28.4% to 29.3%), 24.4% (95% CI: 24.0% to 24.8%) and 10.8% (95% CI: 10.5% to 11.1%), respectively. The prevalence was higher in female, elderly, longer diabetes duration and higher glycated hemoglobin groups. CONCLUSION: This study performed, a nationwide, multicenter, DL-based DR screening and the results indicated the importance and feasibility of DR screening in clinical practice with this system deployed at diabetes centers. TRIAL REGISTRATION NUMBER: NCT04240652.
format Online
Article
Text
id pubmed-7580048
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-75800482020-10-27 Artificial intelligence-enabled screening for diabetic retinopathy: a real-world, multicenter and prospective study Zhang, Yifei Shi, Juan Peng, Ying Zhao, Zhiyun Zheng, Qidong Wang, Zilong Liu, Kun Jiao, Shengyin Qiu, Kexin Zhou, Ziheng Yan, Li Zhao, Dong Jiang, Hongwei Dai, Yuancheng Su, Benli Gu, Pei Su, Heng Wan, Qin Peng, Yongde Liu, Jianjun Hu, Ling Ke, Tingyu Chen, Lei Xu, Fengmei Dong, Qijuan Terzopoulos, Demetri Ning, Guang Xu, Xun Ding, Xiaowei Wang, Weiqing BMJ Open Diabetes Res Care Epidemiology/Health services research INTRODUCTION: Early screening for diabetic retinopathy (DR) with an efficient and scalable method is highly needed to reduce blindness, due to the growing epidemic of diabetes. The aim of the study was to validate an artificial intelligence-enabled DR screening and to investigate the prevalence of DR in adult patients with diabetes in China. RESEARCH DESIGN AND METHODS: The study was prospectively conducted at 155 diabetes centers in China. A non-mydriatic, macula-centered fundus photograph per eye was collected and graded through a deep learning (DL)-based, five-stage DR classification. Images from a randomly selected one-third of participants were used for the DL algorithm validation. RESULTS: In total, 47 269 patients (mean (SD) age, 54.29 (11.60) years) were enrolled. 15 805 randomly selected participants were reviewed by a panel of specialists for DL algorithm validation. The DR grading algorithms had a 83.3% (95% CI: 81.9% to 84.6%) sensitivity and a 92.5% (95% CI: 92.1% to 92.9%) specificity to detect referable DR. The five-stage DR classification performance (concordance: 83.0%) is comparable to the interobserver variability of specialists (concordance: 84.3%). The estimated prevalence in patients with diabetes detected by DL algorithm for any DR, referable DR and vision-threatening DR were 28.8% (95% CI: 28.4% to 29.3%), 24.4% (95% CI: 24.0% to 24.8%) and 10.8% (95% CI: 10.5% to 11.1%), respectively. The prevalence was higher in female, elderly, longer diabetes duration and higher glycated hemoglobin groups. CONCLUSION: This study performed, a nationwide, multicenter, DL-based DR screening and the results indicated the importance and feasibility of DR screening in clinical practice with this system deployed at diabetes centers. TRIAL REGISTRATION NUMBER: NCT04240652. BMJ Publishing Group 2020-10-21 /pmc/articles/PMC7580048/ /pubmed/33087340 http://dx.doi.org/10.1136/bmjdrc-2020-001596 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Epidemiology/Health services research
Zhang, Yifei
Shi, Juan
Peng, Ying
Zhao, Zhiyun
Zheng, Qidong
Wang, Zilong
Liu, Kun
Jiao, Shengyin
Qiu, Kexin
Zhou, Ziheng
Yan, Li
Zhao, Dong
Jiang, Hongwei
Dai, Yuancheng
Su, Benli
Gu, Pei
Su, Heng
Wan, Qin
Peng, Yongde
Liu, Jianjun
Hu, Ling
Ke, Tingyu
Chen, Lei
Xu, Fengmei
Dong, Qijuan
Terzopoulos, Demetri
Ning, Guang
Xu, Xun
Ding, Xiaowei
Wang, Weiqing
Artificial intelligence-enabled screening for diabetic retinopathy: a real-world, multicenter and prospective study
title Artificial intelligence-enabled screening for diabetic retinopathy: a real-world, multicenter and prospective study
title_full Artificial intelligence-enabled screening for diabetic retinopathy: a real-world, multicenter and prospective study
title_fullStr Artificial intelligence-enabled screening for diabetic retinopathy: a real-world, multicenter and prospective study
title_full_unstemmed Artificial intelligence-enabled screening for diabetic retinopathy: a real-world, multicenter and prospective study
title_short Artificial intelligence-enabled screening for diabetic retinopathy: a real-world, multicenter and prospective study
title_sort artificial intelligence-enabled screening for diabetic retinopathy: a real-world, multicenter and prospective study
topic Epidemiology/Health services research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7580048/
https://www.ncbi.nlm.nih.gov/pubmed/33087340
http://dx.doi.org/10.1136/bmjdrc-2020-001596
work_keys_str_mv AT zhangyifei artificialintelligenceenabledscreeningfordiabeticretinopathyarealworldmulticenterandprospectivestudy
AT shijuan artificialintelligenceenabledscreeningfordiabeticretinopathyarealworldmulticenterandprospectivestudy
AT pengying artificialintelligenceenabledscreeningfordiabeticretinopathyarealworldmulticenterandprospectivestudy
AT zhaozhiyun artificialintelligenceenabledscreeningfordiabeticretinopathyarealworldmulticenterandprospectivestudy
AT zhengqidong artificialintelligenceenabledscreeningfordiabeticretinopathyarealworldmulticenterandprospectivestudy
AT wangzilong artificialintelligenceenabledscreeningfordiabeticretinopathyarealworldmulticenterandprospectivestudy
AT liukun artificialintelligenceenabledscreeningfordiabeticretinopathyarealworldmulticenterandprospectivestudy
AT jiaoshengyin artificialintelligenceenabledscreeningfordiabeticretinopathyarealworldmulticenterandprospectivestudy
AT qiukexin artificialintelligenceenabledscreeningfordiabeticretinopathyarealworldmulticenterandprospectivestudy
AT zhouziheng artificialintelligenceenabledscreeningfordiabeticretinopathyarealworldmulticenterandprospectivestudy
AT yanli artificialintelligenceenabledscreeningfordiabeticretinopathyarealworldmulticenterandprospectivestudy
AT zhaodong artificialintelligenceenabledscreeningfordiabeticretinopathyarealworldmulticenterandprospectivestudy
AT jianghongwei artificialintelligenceenabledscreeningfordiabeticretinopathyarealworldmulticenterandprospectivestudy
AT daiyuancheng artificialintelligenceenabledscreeningfordiabeticretinopathyarealworldmulticenterandprospectivestudy
AT subenli artificialintelligenceenabledscreeningfordiabeticretinopathyarealworldmulticenterandprospectivestudy
AT gupei artificialintelligenceenabledscreeningfordiabeticretinopathyarealworldmulticenterandprospectivestudy
AT suheng artificialintelligenceenabledscreeningfordiabeticretinopathyarealworldmulticenterandprospectivestudy
AT wanqin artificialintelligenceenabledscreeningfordiabeticretinopathyarealworldmulticenterandprospectivestudy
AT pengyongde artificialintelligenceenabledscreeningfordiabeticretinopathyarealworldmulticenterandprospectivestudy
AT liujianjun artificialintelligenceenabledscreeningfordiabeticretinopathyarealworldmulticenterandprospectivestudy
AT huling artificialintelligenceenabledscreeningfordiabeticretinopathyarealworldmulticenterandprospectivestudy
AT ketingyu artificialintelligenceenabledscreeningfordiabeticretinopathyarealworldmulticenterandprospectivestudy
AT chenlei artificialintelligenceenabledscreeningfordiabeticretinopathyarealworldmulticenterandprospectivestudy
AT xufengmei artificialintelligenceenabledscreeningfordiabeticretinopathyarealworldmulticenterandprospectivestudy
AT dongqijuan artificialintelligenceenabledscreeningfordiabeticretinopathyarealworldmulticenterandprospectivestudy
AT terzopoulosdemetri artificialintelligenceenabledscreeningfordiabeticretinopathyarealworldmulticenterandprospectivestudy
AT ningguang artificialintelligenceenabledscreeningfordiabeticretinopathyarealworldmulticenterandprospectivestudy
AT xuxun artificialintelligenceenabledscreeningfordiabeticretinopathyarealworldmulticenterandprospectivestudy
AT dingxiaowei artificialintelligenceenabledscreeningfordiabeticretinopathyarealworldmulticenterandprospectivestudy
AT wangweiqing artificialintelligenceenabledscreeningfordiabeticretinopathyarealworldmulticenterandprospectivestudy